Foliglurax clinical trials
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses foliglurax is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses foliglurax is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)TerminatedPhase 1H. Lundbeck A/SNCT04175132Written as foligluraxHow we know
- Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy SubjectsTerminatedPhase 1H. Lundbeck A/SNCT04322227Written as Foliglurax 10 mg (treatment A)How we know
- Effects of Repeated Doses of Foliglurax on Drug Metabolizing Enzymes in Healthy SubjectsCompletedPhase 1H. Lundbeck A/SNCT04275115Written as FoligluraxHow we know
- Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's PatientsCompletedPhase 2Prexton TherapeuticsNCT03162874Written as PXT002331 - dose 1How we know
- What the Body Does to Foliglurax in Healthy VolunteersCompletedPhase 1H. Lundbeck A/SNCT04002895Written as FoligluraxHow we know
- Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)WithdrawnPhase 2Prexton TherapeuticsNCT03331848Written as PXT002331 - 20mgHow we know
- A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female SubjectsCompletedPhase 1Prexton TherapeuticsNCT02639221Written as PXT002331How we know
Codes
What other systems call foliglurax · ClinicalTrials.gg INT002073
- UNII (FDA) FR50CP1D6WFOLIGLURAXConfirmed FDA, Wikidata
- Wikidata Q39050138foligluraxConfirmed FDA, Wikidata
- NCI Thesaurus C170000FoligluraxOne source FDA
- DrugBank DB15292One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FR50CP1D6W | FOLIGLURAX | Confirmed FDA, Wikidata |
| Wikidata | Q39050138 | foliglurax | Confirmed FDA, Wikidata |
| NCI Thesaurus | C170000 | Foliglurax | One source FDA |
| DrugBank | DB15292 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.